Treatment Preference for Alzheimer’s Disease: A Multicriteria Decision Analysis with Caregivers, Neurologists, and Payors

• Published in: Neurology and therapy 2023-02, Vol.12 (1), p.211-227
• Main Authors: Dranitsaris, George, Zhang, Quanwu, Quill, Alex, Mu, Lin, Weyrer, Christopher, Dysdale, Erik, Neumann, Peter, Tahami Monfared, Amir Abbas
• Format: Article
• Language: English
• Subjects: Internal Medicine; Medicine; Medicine & Public Health; Neurology; Original Research
• ISSN: 2193-8253; 2193-6536
• DOI: 10.1007/s40120-022-00423-y

Introduction Alzheimer’s disease (AD) is a chronic neurodegenerative disorder associated with a high burden of illness. New therapies under development include agents that target amyloid-beta (Aβ), a key component in AD pathogenesis. Understanding the decision-making process for new AD drugs would help determine if such therapies should be adopted by society. Multicriteria decision analysis (MCDA) was applied to three key stakeholder groups to assess treatment alternatives for AD based on a multitude of decision trade-offs covering main components of care. Methods AD caregivers ( n  = 117), neurologists ( n  = 90), and payors ( n  = 90) from the USA received an online survey. The decision problem was broken down into four decision criterion and 12 subcriteria for two treatment scenarios: an Aβ-targeted therapy vs. the standard of care (SOC). Respondents were asked to indicate how much they preferred one option over another on a scale from 1 (equal preference) to 9 (high preference) based on each criterion and subcriterion. The decision criteria and subcriteria were weighted and presented as partial utility scores (pUS), with higher scores suggesting an increased preference for that decision-making component. Results Caregivers and payors applied the highest value to need for intervention (mean pUS = 0.303 and 0.259) and clinical outcomes (mean pUS = 0.286 and 0.377). In contrast, neurologists placed the highest value on clinical outcomes and types of benefits (mean pUS = 0.436 and 0.248). When decision subcriteria were examined, efficacy (mean pUS = 0.115, 0.219, and 0.166) and the type of patient benefits (mean pUS = 0.135, 0.178, and 0.126) were among the most valued by caregivers, neurologists, and payors. Conclusion All groups placed the highest value on drug efficacy and types of benefit derived by patients. In contrast, cost implications were among the least important aspects in their decision-making.